Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression

Cell Reports(2023)10.1016/j.celrep.2023.112599Source: DataRank Database

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression is a research paper published in Cell Reports (2023). On theSindex it has a DataRank of 0. It has been cited 31 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access31 citations

Download PDF

Cite:

Linked data & code

geo rrid

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.84)OA: goldTopics (42)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Faezzah Baharom ORCID,Ahad Khalilnezhad ORCID,Sloane Christian Fussell ORCID,Dalton Hermans ORCID,Alexander M. Schrager

Live enrichment

PubMed:37279110 PMC:PMC10592466 OpenAlex:https://openalex.org/W4379600393

Swiss National Science Foundation

Grant: 155374

Development of viral vectored vaccines for MAGE-expressing tumours

Intramural NIH HHS

Grant: Z99 AI999999

FWCI

2.84

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.cell.com/article/S2211124723006101/pdf

publisherhttp://www.cell.com/article/S2211124723006101/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124723006101?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124723006101?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.celrep.2023.112599

Fields of Study

Immunotherapy and Immune ResponsesImmune Cell Function and InteractionCancer Immunotherapy and Biomarkers0301 basic medicine03 medical and health sciences

MeSH Terms

Adjuvants, ImmunologicAnimalsGenetic VectorsHumansVaccinationCD8-Positive T-LymphocytesMiceAdaptive Immunity

Keywords

HeterologousVaccinationBiologyImmunologyCD8Cytotoxic T cellInnate immune systemCancer researchAntigenVirologyImmune systemGeneticsGeneCancer vaccineHeterologous Prime BoostCp: ImmunologyCp: CancerQH301-705.5Genetic VectorsGenetics and Molecular BiologyCD8-Positive T-LymphocytesAdaptive ImmunityArticleMiceAdjuvants, ImmunologicGeneral BiochemistryHumansAnimalsBiology (General)

Sustainable Development Goals

SDG 0: Good health and well-being

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression

FAIR Checklist

Authors (14)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)